Avidity Biosciences Inc (RNA)
42.56
-1.09
(-2.50%)
USD |
NASDAQ |
Nov 21, 16:00
42.55
-0.01
(-0.02%)
After-Hours: 20:00
Avidity Biosciences Debt to Equity Ratio: 0.00 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.0588 |
| December 31, 2019 | -0.0695 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-0.0695
Minimum
Dec 2019
0.0588
Maximum
Mar 2020
-0.0005
Average
--
Median
Jun 2020
Debt to Equity Ratio Benchmarks
| Sarepta Therapeutics Inc | 1.005 |
| Vertex Pharmaceuticals Inc | 0.00 |
| Natera Inc | 0.4178 |
| Entrada Therapeutics Inc | 0.00 |
| Alnylam Pharmaceuticals Inc | 31.64 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.641B |
| Total Liabilities (Quarterly) | 137.39M |
| Shareholders Equity (Quarterly) | 1.503B |
| Current Ratio | 17.76 |